
The study reports data from EMPEROR‐Preserved according to prespecified endpoints of DELIVER. Using the endpoint definitions from DELIVER, the primary outcome was 13.1% in the empagliflozin and 16.8% in the placebo group. Findings from the EMPEROR‐Preserved were modestly altered when analyzed using cardiovascular trial endpoint definitions of the DELIVER trial. For the composite renal endpoint, the effect of empagliflozin became statistically significant in patients with LVEF <60% using the DELIVER definition.
Like
Save
Share